Regal-Beloit Corp (RBC) 54.89 $RBC Regal Beloit (RBC)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Regal-Beloit Corp (RBC) 54.89 $RBC

Regal Beloit (RBC) Plagued by Various Macroeconomic Issues
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 8:54AM CDT
On Jun 14, Zacks Investment Research updated the research report on industrial goods manufacturer Regal Beloit Corporation (RBC).
ETN: 58.21 (-4.61), RBC: 54.89 (-4.00), ESE: 39.59 (-1.77), ENS: 59.18 (-4.91)

Regal Beloit Corporation To Present At Stifel 2016 Industrials Conference
PR Newswire - Tue Jun 07, 12:40AM CDT
Regal Beloit Corporation (NYSE: RBC) will be presenting at the Stifel 2016 Industrials Conference on June 13, 2016 at 12:15 pm CDT (1:15 pm EDT).
RBC: 54.89 (-4.00)

Regal Beloit Corporation to Present at Deutsche Bank 2016 Global Industrials and Materials Summit
PR Newswire - Tue May 31, 6:57PM CDT
Regal Beloit Corporation (NYSE: RBC) will be presenting at the Deutsche Bank 2016 Global Industrials and Materials Summit on June 8, 2016 at 3:30 pm CDT (4:30 pm EDT).
RBC: 54.89 (-4.00), DB: 14.75 (-3.09)

Downgrade Alert for Regal-Beloit (RBC)
Comtex SmarTrend(R) - Thu May 12, 3:19AM CDT
Regal-Beloit (NYSE:RBC) was downgraded from Overweight to Equal Weight at Morgan Stanley today. The stock closed yesterday at $57.43 on volume of 853,000 shares, above average daily volume of 280,000. Regal-Beloit Corporation manufactures a line of mechanical products that control motion and torque and electrical products such as motors and generators. The Company's products include gearboxes, automotive transmissions, rotary cutting tools, electric motors, and electric generators. Regal-Beloit sells its products to distributors, original equipment manufacturers, and end users.
RBC: 54.89 (-4.00)

Regal Beloit (RBC) Misses Q1 Earnings on Lower Revenues
Zacks Equity Research - Zacks Investment Research - Tue May 10, 6:48AM CDT
Regal Beloit Corporation (RBC) reported lackluster first-quarter 2016 results with a significant year-over-year decline in net sales and adjusted earnings owing to macroeconomic woes.
ETN: 58.21 (-4.61), RBC: 54.89 (-4.00), FELE: 33.85 (-1.52), ESE: 39.59 (-1.77)

Machinery Stocks to Watch for Earnings: LXFR, SNHY, CUI, RBC
Zacks Equity Research - Zacks Investment Research - Fri May 06, 8:47AM CDT
Let's take a look at how Luxfer Holdings PLC (LXFR), Sun Hydraulics Corp. (SNHY), CUI Global, Inc. (CUI) and Regal Beloit Corporation (RBC) might fare in Q1.
RBC: 54.89 (-4.00), SNHY: 29.11 (-2.58), LXFR: 11.97 (-0.73), CUI: 4.95 (-0.22)

Should You Buy Regal Beloit (RBC) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 7:42AM CDT
Regal Beloit (RBC) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory.
RBC: 54.89 (-4.00)

Regal Beloit Corporation To Present At 2016 Wells Fargo Securities Industrial and Construction Conference
PR Newswire - Wed May 04, 9:20AM CDT
Regal Beloit Corporation (NYSE: RBC) will be presenting at the 2016 Wells Fargo Securities Industrial and Construction Conference on May 11, 2016 at 10:20 am CDT (11:20 am EDT).
RBC: 54.89 (-4.00), WFC: 45.89 (-2.02)

Milacron Holdings (MCRN) Q1 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:28PM CDT
Milacron Holdings Corp. (MCRN) is set to release first-quarter 2016 results before the opening bell on May 5.
NDSN: 81.53 (-5.84), VTNR: 1.27 (-0.05), RBC: 54.89 (-4.00), MCRN: 15.29 (-1.30)

Will Q1 Earnings Hold a Surprise for Xylem (XYL) Stock?
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 2:34PM CDT
Xylem Inc. (XYL) is scheduled to report first-quarter 2016 results before the opening bell on May 3, 2016.
XYL: 44.28 (-2.07), RBC: 54.89 (-4.00), CMPR: 92.35 (-5.64), ACCO: 10.23 (-0.45)

Rexnord (RXN) to Exit RHP Product Line, Reviews '16 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 6:14PM CDT
Rexnord Corporation (RXN) recently announced its decision to exit its non-strategic RHF product line. The company also reviewed its guidance for fourth-quarter and fiscal year 2016.
PPSI: 5.27 (-0.23), RBC: 54.89 (-4.00), EMR: 50.83 (-2.84), RXN: 19.58 (-1.63)

A.O. Smith (AOS) Q1 Earnings Top, Revenues Miss Estimates
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 9:17AM CDT
A.O. Smith Corp. (AOS) continued with its earnings streak in first-quarter 2016, with earnings per share of 83 cents surpassing the Zacks Consensus Estimate of 77 cents by 7.8%.
RBC: 54.89 (-4.00), EMR: 50.83 (-2.84), RXN: 19.58 (-1.63), AOS: 84.02 (-2.66)

Sealed Air (SEE) Q1 Earnings: Can the Stock Pull a Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 1:41PM CDT
Sealed Air Corporation (SEE) is expected to report first-quarter 2016 results on Apr 28, before the market opens.
SEE: 45.72 (-2.13), FLOW: 27.52 (-2.80), RBC: 54.89 (-4.00), EMR: 50.83 (-2.84)

Paper Stock WestRock (WRK) Likely to Beat Q2 Earnings
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 9:12AM CDT
We expect WestRock Company (WRK) to beat expectations when it reports Q2 numbers on Apr 29, before the market opens.
FLOW: 27.52 (-2.80), WRK: 38.76 (-2.75), RBC: 54.89 (-4.00), EMR: 50.83 (-2.84)

Top 4 Industrial Stocks Likely to Beat Q1 Earnings Estimates
Zacks Equity Research - Zacks Investment Research - Fri Apr 22, 12:36PM CDT
Huge investments in infrastructure development can improve industrial products demand and also create new jobs.
JBT: 61.53 (-2.00), FLOW: 27.52 (-2.80), RBC: 54.89 (-4.00), ROK: 113.11 (-7.41)

Regal-Beloit Has Returned 21.5% Since SmarTrend Recommendation (RBC)
Comtex SmarTrend(R) - Wed Apr 20, 1:38PM CDT
SmarTrend identified an Uptrend for Regal-Beloit (NYSE:RBC) on February 26th, 2016 at $54.76. In approximately 2 months, Regal-Beloit has returned 21.53% as of today's recent price of $66.55.
RBC: 54.89 (-4.00)

EnerSys Buys Enser's Assets to Boost Defense Operations
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 5:05PM CDT
EnerSys (ENS) is set to acquire certain assets of Enser Corporation in its bid to expand its footprint in the aerospace and defense markets.
RBC: 54.89 (-4.00), EMR: 50.83 (-2.84), ESE: 39.59 (-1.77), ENS: 59.18 (-4.91)

Regal Beloit Corporation To Hold First Quarter 2016 Earnings Conference Call On Tuesday, May 10, 2016
PR Newswire - Thu Apr 14, 3:15PM CDT
Regal Beloit Corporation (NYSE: RBC) announced today that it plans to release its first quarter 2016 financial results after the market closes on Monday, May 9, 2016.
RBC: 54.89 (-4.00)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 2

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 1

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 1

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 5

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 1

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 7

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 8

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 3

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 2

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading

Top 5 Most Recently Viewed Articles

Acumen Pharmaceuticals to Showcase Innovations at Conference

Updated Category News Views 115

Acumen Pharmaceuticals to Present at Health Conference Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a pioneering clinical-stage biopharmaceutical company, is set to engage in a significant fireside chat at the 7th Annual Evercore ISI HealthCONx Conference. This event will happen shortly, providing a platform for Acumen to discuss their innovative approaches to tackling...

Continue Reading
Chanson International Holding Reports Fiscal Year 2025 Mid-Year Results

Updated Category News Views 192

Chanson International Holding Reports Mid-Year Financial Results Chanson International Holding (NASDAQ: CHSN) has recently unveiled its financial performance for the first half of the fiscal year 2025. As a key player in the bakery and beverage sectors, the company's unaudited results signify its resilience in a fluctuating market. Overview of Financial Performance...

Continue Reading
Investors Are Strategically Analyzing REGN Options Activity

Updated Category News Views 66

Examining Recent Changes in REGN Options There's been a noteworthy shift in sentiment among financial experts regarding Regeneron Pharmaceuticals. A recent analysis of the trading patterns in REGN options has revealed a blend of bullish and bearish movements in the market. This information serves as a foundation for understanding the current factors that are shaping...

Continue Reading
Analysts Raise Price Targets for CVS After Strong Earning Report

Updated Category News Views 99

CVS Health Exceeds Expectations with Recent Earnings CVS Health Corp (NYSE: CVS) delivered an impressive earnings report for its fourth quarter, showing robust sales numbers that surpassed analysts' expectations. The company announced fourth-quarter sales totaling an incredible $97.71 billion, outpacing the consensus estimate of $97.19 billion. Adjusted Earnings Report...

Continue Reading
Healthcare Triangle and Teyame AI Join Forces to Innovate Patient Engagement

Updated Category News Views 161

Healthcare Triangle Announces Strategic Partnership with Teyame AI Healthcare Triangle, Inc. (Nasdaq: HCTI) is excited to share its recent agreement with Teyame AI LLC, a visionary corporation aiming to revolutionize customer experience through artificial intelligence. This partnership is a transformative step that will not only enhance HCTI's SaaS capabilities but is...

Continue Reading